ProQR Therapeutics (PRQR) Liabilities and Shareholders Equity (2021 - 2024)
Historic Liabilities and Shareholders Equity for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $179.5 million.
- ProQR Therapeutics' Liabilities and Shareholders Equity rose 2098.05% to $179.5 million in Q4 2024 from the same period last year, while for Sep 2025 it was $179.5 million, marking a year-over-year increase of 2098.05%. This contributed to the annual value of $181.8 million for FY2024, which is 2188.19% up from last year.
- ProQR Therapeutics' Liabilities and Shareholders Equity amounted to $179.5 million in Q4 2024, which was up 2098.05% from $148.4 million recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Liabilities and Shareholders Equity ranged from a high of $110.5 billion in Q1 2021 and a low of $122.7 million during Q3 2022
- Its 4-year average for Liabilities and Shareholders Equity is $8.7 billion, with a median of $179.5 million in 2024.
- Per our database at Business Quant, ProQR Therapeutics' Liabilities and Shareholders Equity tumbled by 9980.68% in 2022 and then surged by 2597.08% in 2023.
- ProQR Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $239.8 million in 2021, then fell by 27.1% to $174.8 million in 2022, then decreased by 15.12% to $148.4 million in 2023, then increased by 20.98% to $179.5 million in 2024.
- Its Liabilities and Shareholders Equity stands at $179.5 million for Q4 2024, versus $148.4 million for Q4 2023 and $154.6 million for Q3 2023.